Physician profile
Bassem Philip
NPI 1598061129
$4,476.06
in general payments reported to CMS, 2019-2025
28 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $162 · 2022: $500 · 2023: $808 · 2024: $1,673 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,617.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $618.98 | 2022-2025 | |
| Novo Nordisk INC | $430.40 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Corium, LLC | $373.20 | 2022-2025 | Azstarys |
| Lilly USA, LLC | $343.82 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Supernus Pharmaceuticals, INC. | $305.00 | 2023-2024 | Qelbree, Qelbree |
| Abbvie INC. | $297.83 | 2022-2025 | |
| Amgen INC. | $267.17 | 2023-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $240.48 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $234.73 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $215.43 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.36 | 2022-2025 | Xifaxan |
| Exact Sciences Corporation | $158.71 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $124.41 | 2024-2025 | Veozah |
| Medtronic, INC. | $119.79 | 2025 | Endoflip |
| Astrazeneca Pharmaceuticals Lp | $112.23 | 2022-2025 | Airsupra, Breztri |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $93.04 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $79.85 | 2023-2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Collegium Pharmaceutical, INC. | $51.42 | 2025 | Jornay Pm |
| Phathom Pharmaceuticals, INC. | $35.82 | 2024-2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $34.50 | 2023-2025 | Quviviq, Quviviq |
| Ironshore Pharmaceuticals INC. | $24.81 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.67 | 2022 | |
| Sanofi Pasteur INC. | $21.15 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.66 | 2023 | |
| Abbott Laboratories | $19.51 | 2025 | Freestyle Libre 3 |
| Relievant Medsystems, INC. | $17.11 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.65 | 2022 | |
| Glaxosmithkline, LLC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassem Philip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.